Mode
Text Size
Log in / Sign up
N/A N=55 Randomized Single-blind Prevention

Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis

Venous Thrombosis · Deep Vein Thrombosis

Enrolled (actual)
55
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
DVT-3000 (Device); SCD Express (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Seoul National University Hospital
Primary completion
Jan 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Deep Vein Thrombosis
14; 15; 9; 12; 1; 1 0.785
SECONDARY
Peak Velocity
24.8; 22.8 0.195
SECONDARY
Mean Velocity
10.0; 9.7 0.722
SECONDARY
Peak Volume Flow
205.3; 176.4 0.158
SECONDARY
Total Volume Flow
160.9; 144.2 0.301
SECONDARY
Expelled Total Volume
7214.0; 4342.0; 6102.8; 3334.5 <0.001 sig
SECONDARY
Expelled Peak Volume
999.8; 633.1; 904.0; 525.5 <0.001 sig
SECONDARY
Augmented PV
62.8; 56.2; 57.1; 58.5 0.929
SECONDARY
Augmented MV
20.4; 18.2; 33.1; 18.3
SECONDARY
Augmented PVF
666.5; 514.6; 602.7; 465.0 0.008 sig
SECONDARY
Augmented TVF
400.7; 324.2; 339.0; 271.2 0.132
SECONDARY
Cycling Rate
90; 78.9

Summary

Various kinds of intermittent pneumatic compression devices (IPC) with particular ways of compression have been developed and used for prevention of deep vein thrombosis. There are still some controversies about the physiologic properties and clinical impact of numerous issues including the variety of the cuff length, inflation rate, compression sequence, compression-relaxation cycle rate, and pressure generation characteristics. This study is designed to compare clinical efficacies as well as venous hemodynamic improvements between Simultaneous bilateral compression with fixed venous refill time versus alternate compression with adjusted refill time

Eligibility Criteria

Inclusion Criteria

  • the patients who undergo total knee replacement arthroplasty

Exclusion Criteria

  • (1) chronic superficial or deep venous insufficiency, (2) venous anomalies like duplication of the superficial femoral vein, (3) previous venous thromboembolism history, (4) being under anticoagulation therapy, (5) severe arteriosclerosis obliterans without palpable dorsalis pedis pulse, (6) open fracture, hemorrhagic condition, or extensive dermatitis at lower legs, (7) congestive heart failure. Additional exclusion criteria included a documented malignant tumor, because pharmacologic prophylaxis with anticoagulants would be more reasonable in this case.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01779648). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search